FindTrial
Sign In

Exploration of the Syndrome Basis of Primary Liver Cancer with Damp-Heat Syndrome of Liver and Gallbladder Based on the Mechanism of Bacterial Translocation Mediated AQP3 Promoting Immune Escape

Exploration of the Syndrome Basis of Primary Liver Cancer with Damp-Heat Syndrome of Liver and Gallbladder Based on the Mechanism of Bacterial Translocation Mediated AQP3 Promoting Immune Escape

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082028
Enrollment
Unknown
Registered
2024-03-19
Start date
2024-04-05
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

Control group:None
Primary liver cancer group:None
Primary Liver Cancer with Damp-Heat Syndrome of Liver and Gallbladder group:None
Hepatic cyst group:None

Sponsors

Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria for PLC: ? Patients diagnosed with damp-heat syndrome in primary liver cancer (PLC) and those with non-damp-heat syndrome in PLC; ? Age = 18 years; ? No use of antibiotics or other microbial preparations within two weeks; ? Good compliance of patients, and written informed consent signed. Inclusion criteria for hepatic cysts: ? Patients diagnosed with hepatic cysts; ? Age = 18 years; ? No use of antibiotics or other microbial preparations within two weeks; ? Good compliance of patients, and written informed consent signed. Inclusion criteria for the healthy control group: ? Healthy adult males; ? No use of antibiotics or other microbial preparations within two weeks; ? Good compliance of patients, and written informed consent signed.

Exclusion criteria

Exclusion criteria: Exclusion criteria for PLC: Patients with secondary liver cancer; Patients simultaneously diagnosed with other malignant tumors; Poor compliance; Pregnant or lactating women; Patients with mental illness. Exclusion criteria for hepatic cysts: Patients with severe heart, liver, lung, or kidney diseases; Patients with hepatic cyst infection; Poor compliance; Pregnant or lactating women; Patients with mental illness. Exclusion criteria for the healthy control group: Poor compliance.

Design outcomes

Primary

MeasureTime frame
Traditional Chinese Medicine syndrome;Alpha-fetoprotein;Liver function;Tumor size;Tumor staging;Coagulation function;Gut microbiome diversity;Plasma microbiota diversity;Microbial diversity in liver histological samples;Activation and proliferation of peripheral blood CD8+ T cells;Cytotoxicity of peripheral blood CD8+ T cells;Expression of GZMB in peripheral blood CD8+ T cells;Expression of perforin in peripheral blood CD8+ T cells;Plasma LPS levels;Plasma IL-1ßlevels;Plasma TNF-a levels;Plasma IL-6 levels;LPS content in liver histological samples;TLR4 expression in liver histological samples;MyD88expression in liver histological samples;Infiltration of CD8+ T cells in liver histological samples;AQP3 expression in liver histological samples;MHC-I expression in liver histological samples;LC3 expression in liver histological samples;Beclin1 expression in liver histological samples;P62expression in liver histological samples;Levels of IFN-? in cell supernatant;Apoptosis of A375 cells;—

Countries

China

Contacts

Public ContactWang Yao

Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, China.

wangyaoxzy@163.com+86 151 3949 6771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026